{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:35:13Z","timestamp":1793936113443,"version":"4.8.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003161","name":"National Alopecia Areata Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003161","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jaip.2023.03.011","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T04:24:27Z","timestamp":1679372667000},"page":"1361-1373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations"],"prefix":"10.1016","volume":"11","author":[{"given":"Sneha","family":"Butala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Castelo-Soccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.03.011_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib5","series-title":"(dupilumab) Injection, for Subcutaneous Use","year":"2022"},{"key":"10.1016\/j.jaip.2023.03.011_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.03.011_bib7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1365-2249.1998.00646.x","article-title":"Effects of anti-IL-4 receptor monoclonal antibody on in\u00a0vitro T cell cytokine levels: IL-4 production by T cells from non-atopic donors","volume":"113","author":"Bullens","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib9","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.03.011_bib10","unstructured":"Sanofi. Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are na\u00efve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID). 2024. Accessed April 4, 2023. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT04180488&cntry=&state=&city=&dist=."},{"key":"10.1016\/j.jaip.2023.03.011_bib11","unstructured":"Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS), 2022. Accessed April 4, 2023. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT04681729&cntry=&state=&city=&dist=."},{"key":"10.1016\/j.jaip.2023.03.011_bib12","unstructured":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME), 2021. Accessed April 4, 2023. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT04183335&cntry=&state=&city=&dist=."},{"key":"10.1016\/j.jaip.2023.03.011_bib13","unstructured":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2), 2021. Accessed April 4, 2023. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT04202679&cntry=&state=&city=&dist=."},{"key":"10.1016\/j.jaip.2023.03.011_bib14","unstructured":"Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE), 2021. Accessed April 4 2023. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT03633617&cntry=&state=&city=&dist=."},{"key":"10.1016\/j.jaip.2023.03.011_bib15","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.011_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Tha\u00e7i","year":"2019","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2023.03.011_bib17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/09546634.2019.1612836","article-title":"Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2","volume":"31","author":"Cork","year":"2020","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jaip.2023.03.011_bib18","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.03.011_bib19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"De Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.03.011_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/pde.14909","article-title":"Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis\u2014a pooled analysis of trial data","volume":"39","author":"Paller","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib25","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1111\/all.15064","article-title":"Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1\/T17 cytokines: a case series study","volume":"76","author":"Bakker","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.03.011_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib29","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaad.2021.06.017","article-title":"Management of inadequate response and adverse effects to dupilumab in atopic dermatitis","volume":"86","author":"Narla","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jdv.17981","article-title":"Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review","volume":"36","author":"Neagu","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2023.03.011_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100042","article-title":"A\u00a0literature review of real-world effectiveness and safety of dupilumab for atopic dermatitis","volume":"1","author":"Kamata","year":"2021","journal-title":"JID Innov"},{"key":"10.1016\/j.jaip.2023.03.011_bib32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.18730","article-title":"Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series","volume":"183","author":"de Wijs","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jaad.2019.06.026","article-title":"Characterizing dupilumab facial redness: a multi-institution retrospective medical record review","volume":"82","author":"Waldman","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib34","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/pde.14799","article-title":"Experience using dupilumab for pediatric atopic dermatitis at a tertiary care center: inadequate response and adverse events","volume":"38","author":"McKenzie","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib35","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","article-title":"Facial and neck erythema associated with dupilumab treatment: a systematic review","volume":"84","author":"Jo","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40257-021-00646-z","article-title":"Dupilumab facial redness\/dupilumab facial dermatitis: a guide for clinicians","volume":"23","author":"Muzumdar","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2023.03.011_bib38","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdcr.2021.12.011","article-title":"Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management","volume":"21","author":"Jay","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2023.03.011_bib40","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib41","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/jdv.18327","article-title":"Facial erythema in patients with atopic dermatitis treated with dupilumab\u2014a descriptive study of morphology and aetiology","volume":"36","author":"Ahn","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2023.03.011_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13555-020-00469-6","article-title":"Real-world experience and laboratory monitoring of dupilumab in patients with moderate to severe atopic dermatitis in a tertiary centre","volume":"11","author":"Kreeshan","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaip.2023.03.011_bib43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-021-00607-6","article-title":"Recommendations for vaccination in children with atopic dermatitis treated with dupilumab: a consensus meeting, 2020","volume":"22","author":"Martinez-Cabriales","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib44","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase iii open-label extension trial (LIBERTY AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jid.2019.05.024","article-title":"IL-4R\u03b1 blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis","volume":"140","author":"Callewaert","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib46","article-title":"Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis","volume":"9","author":"Boguniewicz","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.03.011_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13R\u03b11 and IL-13R\u03b12","volume":"429","author":"Popovic","year":"2017","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jaip.2023.03.011_bib49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib50","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00403-004-0455-6","article-title":"Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis","volume":"295","author":"Tazawa","year":"2004","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaip.2023.03.011_bib51","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1172\/JCI58978","article-title":"Periostin promotes chronic allergic inflammation in response to Th2 cytokines","volume":"122","author":"Masuoka","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2023.03.011_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2023.03.011_bib53","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13\u2013dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib55","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib56","series-title":"Presented at Fall Clinical Dermatology Conference, Las Vegas, NV","article-title":"et al., eds. Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial","author":"Paller","year":"2021"},{"key":"10.1016\/j.jaip.2023.03.011_bib57","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib58","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.03.011_bib60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib61","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jaip.2023.03.011_bib62","series-title":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis","author":"Eli","year":"2021"},{"key":"10.1016\/j.jaip.2023.03.011_bib63","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.011_bib64","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","article-title":"Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)","volume":"159","author":"Simpson","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib66","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: the \"itchy\" cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.03.011_bib67","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A\u00a0sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib68","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.011_bib69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib70","first-page":"3741","article-title":"Regulation of skin barrier function via competition between AHR Axis versus IL-13\/IL-4JAKSTAT6\/STAT3 Axis: pathogenic and therapeutic implications in atopic dermatitis","volume":"9","author":"Furue","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jaip.2023.03.011_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.11.041","article-title":"JAK1\/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis","volume":"147","author":"Klaeschen","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib72","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.03.011_bib73","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.011_bib74","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib75","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.03.011_bib76","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/healthcare9111575","article-title":"Baricitinib: The first JAK inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients","volume":"9","author":"Radi","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.jaip.2023.03.011_bib77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: tesults from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","volume":"85","author":"Simpson","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib78","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/12034754211073661","article-title":"Onset of symptom relief reported in daily diaries of patients with atopic dermatitis treated with baricitinib in a United States clinical trial (BREEZE-AD5)","volume":"26","author":"Rosmarin","year":"2022","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.jaip.2023.03.011_bib79","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib80","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.03.011_bib81","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jdin.2021.05.004","article-title":"Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: results from JADE MONO-2 and JADE COMPARE","volume":"4","author":"Gooderham","year":"2021","journal-title":"JAAD Int"},{"key":"10.1016\/j.jaip.2023.03.011_bib82","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/jdv.17792","article-title":"Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes","volume":"36","author":"Cork","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2023.03.011_bib83","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/jcph.1858","article-title":"Effects of hepatic impairment on the pharmacokinetics of abrocitinib and its metabolites","volume":"61","author":"Wang","year":"2021","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jaip.2023.03.011_bib84","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN Randomized Clinical Trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib85","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s13318-021-00745-6","article-title":"Assessment of the Effects of inhibition or induction of CYP2C19 and CYP2C9 enzymes, or inhibition of OAT3, on the pharmacokinetics of abrocitinib and its metabolites in healthy individuals","volume":"47","author":"Wang","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jaip.2023.03.011_bib86","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 Randomized Clinical Trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib87","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib88","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/bcp.13329","article-title":"Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib","volume":"83","author":"Mohamed","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2023.03.011_bib89","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","article-title":"Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study","volume":"85","author":"Nakagawa","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib90","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","article-title":"Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis","volume":"144","author":"Nakagawa","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib91","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib92","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","article-title":"A\u00a0maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis","volume":"23","author":"Bissonnette","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib93","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","article-title":"Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies","volume":"22","author":"Gong","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib94","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2023.03.011_bib95","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.03.011_bib96","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823002957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823002957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:36:52Z","timestamp":1761975412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823002957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2213219823002957"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.03.011","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}